Induction of caspase mediated apoptosis and down-regulation of nuclear factor-κB and Akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells

Journal of Urology

Volumn 186, Issue 5, 2011, Pages 2084-2093

  Jeon, Hwang Gyun ^a   Yoon, Cheol Yong ^c   Yu, Ji Hyeong ^b   Park, Mi Jeong ^c   Lee, Jung Eun ^c   Jeong, Seong Jin ^c   Hong, Sung Kyu ^c   Byun, Seok Soo ^c   Lee, Sang Eun ^c  

^a CHA University   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

carcinoma; dose response relationship; drug; gemcitabine; trichostatin A; urinary bladder

Indexed keywords

CASPASE; CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN A; CYCLIN B1; CYCLIN D1; GEMCITABINE; I KAPPA B; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; P21 ACTIVATED KINASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN BAD; PROTEIN BAX; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE; TRICHOSTATIN A; X LINKED INHIBITOR OF APOPTOSIS;

ADVANCED CANCER; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER SURVIVAL; CELL COUNT; CELL CYCLE; CLONOGENIC ASSAY; DOWN REGULATION; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CASPASES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 80053941490     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.06.053     Document Type: Article

References (30)

1. H. Masuda, T. Tanaka, and H. Matsuda Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis- diamminedichloroplatinum(II) Cancer Res 50 1990 1863
2. D.R. Herbold, and L. Glaser Interaction of N-acetylmuramic acid L-alanine amidase with cell wall polymers J Biol Chem 250 1975 7231
3. E. Reed Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy Cancer Treat Rev 24 1998 331
4. V. Gregoire, W.N. Hittelman, and J.F. Rosier Chemo-radiotherapy: radiosensitizing nucleoside analogues (review) Oncol Rep 6 1999 949
5. P. Huang, S. Chubb, and L.W. Hertel Action of 2′,2′- difluorodeoxycytidine on DNA synthesis Cancer Res 51 1991 6110
6. W. Plunkett, P. Huang, and V. Gandhi Preclinical characteristics of gemcitabine Anticancer Drugs 6 suppl. 1995 7
7. H.B. Grossman, R.B. Natale, and C.M. Tangen Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 2003 859
8. H. von derMaase, S.W. Hansen, and J.T. Roberts Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 2000 3068
9. H. von der Maase Gemcitabine in advanced bladder cancer Semin Oncol 28 2001 11
10. F. El Karak, and A. Flechon Gemcitabine in bladder cancer Expert Opin Pharmacother 8 2007 3251
11. C.Y. Yoon, M.J. Park, and J.S. Lee The histone deacetylase inhibitor trichostatin a synergistically resensitizes a cisplatin resistant human bladder cancer cell line J Urol 185 2011 1102
12. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 1984 27
13. H. Rikiishi, F. Shinohara, and T. Sato Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid Int J Oncol 30 2007 1181
14. M. Suzuki, M. Endo, and F. Shinohara Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells Cancer Chemother Pharmacol 64 2009 1115
15. M. Dokmanovic, C. Clarke, and P.A. Marks Histone deacetylase inhibitors: overview and perspectives Mol Cancer Res 5 2007 981
16. Y. Chen, W. Shu, and W. Chen Curcumin, both histone deacetylase and p300/CBP-specific inhibitor, represses the activity of nuclear factor kappa B and Notch 1 in Raji cells Basic Clin Pharmacol Toxicol 101 2007 427
17. B.B. Aggarwal Nuclear factor-kappaB: the enemy within Cancer Cell 6 2004 203
18. Y. Takada, A. Gillenwater, and H. Ichikawa Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation J Biol Chem 281 2006 5612
19. G. Levidou, A.A. Saetta, and P. Korkolopoulou Clinical significance of nuclear factor (NF)-kappaB levels in urothelial carcinoma of the urinary bladder Virchows Arch 452 2008 295
20. J.G. Izzo, U. Malhotra, and T.T. Wu Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma J Clin Oncol 24 2006 748
21. Z. Zhang, J. Ma, and N. Li Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer Ann Thorac Surg 82 2006 243
22. L. Yin, G. Laevsky, and C. Giardina Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity J Biol Chem 276 2001 44641
23. J. Bai, A. Demirjian, and J. Sui Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells Biochem Biophys Res Commun 348 2006 1245
24. T.M. Lindstrom, A.R. Mohan, and M.R. Johnson Histone deacetylase inhibitors exert time-dependent effects on nuclear factor-kappaB but consistently suppress the expression of proinflammatory genes in human myometrial cells Mol Pharmacol 74 2008 109
25. C. Nishioka, T. Ikezoe, and J. Yang Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappaB Leuk Res 32 2008 287
26. G. Imre, V. Gekeler, and A. Leja Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation Cancer Res 66 2006 5409
27. J. Yao, L. Duan, and M. Fan NF-kappaB signaling pathway is involved in growth inhibition, G2/M arrest and apoptosis induced by trichostatin A in human tongue carcinoma cells Pharmacol Res 54 2006 406
28. R.R. Rosato, and S. Grant Histone deacetylase inhibitors in cancer therapy Cancer Biol Ther 2 2003 30
29. M. Fournel, M.C. Trachy-Bourget, and P.T. Yan Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors Cancer Res 62 2002 4325
30. A. Batova, L.E. Shao, and M.B. Diccianni The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines Blood 100 2002 3319